KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC

Opinion
Video

A review of adagrasib in the KRYSTAL-1 trial in patients with NSCLC.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Future of HER2-Directed Tumor-Agnostic Therapies
      Future of HER2-Directed Tumor-Agnostic Therapies
      Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
      Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
      Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
      Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
      Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
      Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
      HER2 Key Differences and Current Approaches to Biomarker Testing
      HER2 Key Differences and Current Approaches to Biomarker Testing
      Introduction to HER2-Directed Tumor-Agnostic Approaches
      Introduction to HER2-Directed Tumor-Agnostic Approaches
      The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
      Lung Cancer Home Health Screening Tools May Aid in Triaging LDCT+ Patients
      An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
      Cell-Free DNA Assay Achieves High Negative Predicative Value in Lung Cancer
      Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
      Blood Testing for Lung Cancer May Address Inadequate Screening Utilization
      Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
      Frontline Treatment for EGFR-Mutated Lung Cancer
      Related Content
      Surufatinib/Toripalimab Shows Encouraging Activity in NSCLC and SCLC

      Surufatinib/Toripalimab Shows Encouraging Activity in NSCLC and SCLC

      Tim Cortese
      April 8th 2025
      Article

      Surufatinib/toripalimab elicited an ORR of 57.1% in patients with treatment-naïve NSCLC and 15.8% in patients with pretreated SCLC in a phase 2 trial.

      Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

      Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

      Georgios Evangelou, MD, MSc
      September 16th 2024
      Podcast

      Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

      AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

      AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

      Ariana Pelosci
      April 1st 2025
      Article

      An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.

      Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

      Achieving Health Equity in Lung Cancer Surgery

      Rian M. Hasson Charles, MD, MPH, FACS
      April 1st 2024
      Podcast

      Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

      Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.

      Continuous Second-Line Immunotherapy May Benefit Pretreated Lung Cancer

      Roman Fabbricatore
      March 6th 2025
      Article

      Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.

      AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer

      AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer

      Tim Cortese
      February 5th 2025
      Article

      The diagnostic accuracy of radiologists aided by the eyonis LCS AI software was greatly improved compared with when radiologists were unaided.